Actively Recruiting
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Led by University of Manitoba · Updated on 2026-04-22
75
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and/or severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.
CONDITIONS
Official Title
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm, or acute myeloid leukemia
- Receiving less-intensive chemotherapy (frontline or relapsed/refractory setting)
- Severe thrombocytopenia (platelet count 30 30x10^9/L or 30 50x10^9/L before chemotherapy start)
You will not qualify if you...
- Unlikely to survive more than 30 days as determined by clinical team
- Unable to provide informed consent
- Known allergy to tranexamic acid
- Active thromboembolic disease
- Active ischemic heart disease
- Gross hematuria
- Stage V chronic kidney disease
- Clinically suspected disseminated intravascular coagulation (DIC)
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Actively Recruiting
Research Team
B
Brett Houston, MD, PhD
CONTACT
N
Nora Choi, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here